UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000001312
Receipt No. R000001593
Scientific Title Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer
Date of disclosure of the study information 2008/08/12
Last modified on 2017/01/13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer
Acronym Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer(KSCC0801)
Scientific Title Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer
Scientific Title:Acronym Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer(KSCC0801)
Region
Japan

Condition
Condition Unresectable advanced/recurrent colorectal cancer
Classification by specialty
Gastroenterology Hepato-biliary-pancreatic medicine Hematology and clinical oncology
Gastrointestinal surgery Hepato-biliary-pancreatic surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Phase II

Assessment
Primary outcomes PFS
Key secondary outcomes Response rate,
Safety,
OS

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
75 years-old >=
Gender Male and Female
Key inclusion criteria 1.colorectal cancer, cytologically and/or histrogically
2.Unresectable advanced/recurrent colorectal cancer
3.no prior chemotherapy
4.no prior radiotherapy
5.age: 20-75 years old
6. Performance Status(ECOG):0-2
7.with measurable lesions
8.CT/MRI within 28 days
9.Life expectancy estimated >= 3 months
10.no bleeding tendency
11.Sufficient organ functions
12.witten informed consents
Key exclusion criteria 1. Administering antithrobotic drug within 7 days
2. Serious complications (renal failure or hepatic failure)
3. Serious drug hypersensitivity or a history of drug allergy
4. Peripheral neuropathy
5. Active concomitant malignancy
6. Active infections
7. High blood pressure and diabetic that cannot be controlled
8. symptomatic or asymptomatic but treated heart disease
9. interstitial pnumonitis, pulmonary fibrosis or high-grade pulmonary emphysema
10. histry of mental disturbances or cerebrovascular attach
11. Fresh hemorrhage from digestive tube, intestines tube paralysis, intestinal obstruction and peptic ulcer
12. Current or previous (within one year) history of GI perforation
13. Plerral effusion, peritoneal fluid and pericardial fluid
14. Symptomatic brain metastasis
15. Water solubility diarrhea, in case of the patient who has a colostomy, diarrhea impairs daily life activity
16. Need to treatment with atazanavir sulfate
17. under coutinuous steroid therapy
18. Any surgical treatments including skin-open biopsy, trauma surgery and other more intensive surgery within 4 weeks or aspiration biopsy within one week
19. CV-port procedure within one week
20. Anti-platelets therapy (including aspirin and NSAIDS)
21. history of organ transplantation
22. Traumatic gracture of unrecovery
23. Bevacizumab used previous chemotherapy
24. Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers
25. Other conditions not suitable for this study
Target sample size 51

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Maehara Yoshihiko
Organization Kyushu University
Division name Dpt. of surgery and science
Zip code
Address Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582
TEL 092-631-2920
Email info2@cres-kyushu.or.jp

Public contact
Name of contact person
1st name
Middle name
Last name KSCC
Organization CReS
Division name KSCC
Zip code
Address Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582
TEL 092-631-2920
Homepage URL
Email kscc2@cres-kyushu.or.jp

Sponsor
Institute KSCC
Institute
Department

Funding Source
Organization CReS
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 九州大学(福岡県)
国立病院機構九州医療センター(福岡県)
公立学校共済組合九州中央病院(福岡県)
済生会福岡総合病院(福岡県)
福岡歯科大学医科歯科総合病院(福岡県)
済生会八幡総合病院(福岡県)
新日鐵八幡記念病院(福岡県)
社会保険田川病院(福岡県)
社会保険仲原病院(福岡県)
久留米大学(福岡県)
久留米大学医療センター(福岡県)
社会保険久留米第一病院(福岡県)
聖マリア病院(福岡県)
公立八女総合病院(福岡県)
大牟田市立総合病院(福岡県)
福岡県済生会大牟田病院(福岡県)
麻生飯塚病院(福岡県)
福岡市民病院(福岡県)
有田共立病院(佐賀県)
佐世保市立総合病院(長崎県)
長崎大学(長崎県)
光晴会病院(長崎県)
国立病院機構長崎医療センター(長崎県)
済生会熊本病院(熊本県)
熊本大学(熊本県)
健康保険人吉総合病院(熊本県)
大分県立病院(大分県)
大分赤十字病院(大分県)
国立病院機構大分医療センター(大分県)  
国立病院機構別府医療センター(大分県)
中津市立中津市民病院(大分県)
大分県済生会日田病院(大分県)
小林市立病院(宮崎県)
宮崎県立延岡病院(宮崎県)
社会保険宮崎江南病院(宮崎県)
国立病院機構南九州病院(鹿児島県)
今給黎総合病院(鹿児島県)
潤愛会 鮫島病院(鹿児島県)
鹿児島大学(鹿児島県)
鹿児島厚生連病院(鹿児島県)
済生会川内病院(鹿児島県)
県民健康プラザ鹿屋医療センター(鹿児島県)
鹿児島県立薩南病院(鹿児島県)
浦添総合病院(沖縄県)
中頭病院(沖縄県)
ハートライフ病院(沖縄県)
琉球大学(沖縄県)
北部地区医師会病院(沖縄県)
広島赤十字・原爆病院(広島県)
松山赤十字病院(愛媛県)
防府消化器病センター 防府胃腸病院(山口県)

Other administrative information
Date of disclosure of the study information
2008 Year 08 Month 12 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications http://www.ncbi.nlm.nih.gov/pubmed/26037783
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2008 Year 02 Month 14 Day
Date of IRB
Anticipated trial start date
2008 Year 03 Month 01 Day
Last follow-up date
2010 Year 03 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2008 Year 08 Month 12 Day
Last modified on
2017 Year 01 Month 13 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001593

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.